The evolution of folate supplementation - from one size for all to personalized, precision, poly-paths.

Qiangqiang He, Jianping Li
Author Information
  1. Qiangqiang He: Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, Guangdong Province, China.
  2. Jianping Li: Department of Cardiology, Peking University First Hospital, Beijing 100871, China. ORCID

Abstract

Folate is a crucial nutrient that supports physiological functions. Low folate levels is a risk factor for several diseases, including cardiovascular diseases and neural tube defects. The most used folate supplement is folic acid, a synthetic oxidative form, and folic acid grain fortification is a success story of public health. However, the metabolic conversion of folic acid to bioactive tetrahydrofolate requires several enzymes and cofactors. Therefore, these factors influence its bioavailability and efficacy. In contrast, 5-methyltetrahydrofolate is used directly and participates in one-carbon metabolism, and the use of 5-methyltetrahydrofolate as an alternative folate supplement has increased. The metabolism of 5-methyltetrahydrofolate is primarily dependent on the transmembrane transporter, reduced folate carrier (), and the gene variant is a functional polymorphism that affects folate status indexes. Recent studies demonstrated that the expression of and cystathionine β-synthase, another enzyme required for homocysteine clearance, increases significantly by supplementation with calcitriol (vitamin D3), suggesting that calcitriol intake promotes the bioavailability of folate and has synergistic effects in homocysteine clearance. The advancements in biomedical and cohort studies and clinical trials have enhanced our understanding of the critical roles of folate and the regulation of one-carbon metabolism. We anticipate that the field of folate supplementation is poised to evolve from one size for all to personalized, precision, poly-paths (3Ps), which is a critical measure to meet individual needs, maximize health benefits, and minimize side effects.

Keywords

References

  1. Lancet. 2005 Jan 15-21;365(9455):224-32 [PMID: 15652605]
  2. Br J Nutr. 2007 Oct;98(4):667-75 [PMID: 17617936]
  3. J Transl Int Med. 2020 Jun 30;8(2):71-79 [PMID: 32983929]
  4. Curr Drug Metab. 2012 Oct;13(8):1184-95 [PMID: 22746304]
  5. J Inherit Metab Dis. 2011 Feb;34(1):75-81 [PMID: 20814827]
  6. Epilepsia. 2005 Oct;46(10):1677-83 [PMID: 16190942]
  7. Vitam Horm. 2008;79:99-143 [PMID: 18804693]
  8. Cancer Metastasis Rev. 2007 Mar;26(1):141-52 [PMID: 17333345]
  9. Adv Nutr. 2020 Nov 16;11(6):1510-1528 [PMID: 32503038]
  10. Proc Natl Acad Sci U S A. 2009 Sep 8;106(36):15424-9 [PMID: 19706381]
  11. Biochemistry. 1995 Apr 25;34(16):5660-5 [PMID: 7727426]
  12. Biochem J. 2002 Nov 1;367(Pt 3):629-40 [PMID: 12144527]
  13. Mol Genet Metab. 2001 Jul;73(3):285-6 [PMID: 11461197]
  14. N Engl J Med. 1985 Mar 28;312(13):818-22 [PMID: 3883172]
  15. Drug Metab Dispos. 2014 Apr;42(4):632-49 [PMID: 24396145]
  16. Lancet. 2004 Apr 10;363(9416):1184-6 [PMID: 15081649]
  17. Int J Vitam Nutr Res. 2002 Jan;72(1):46-52 [PMID: 11887752]
  18. Epilepsy Res. 2007 Jun;75(1):52-6 [PMID: 17513090]
  19. Curr Drug Metab. 2002 Apr;3(2):211-23 [PMID: 12003352]
  20. Vitam Horm. 2008;79:83-97 [PMID: 18804692]
  21. Proc Natl Acad Sci U S A. 2019 Aug 27;116(35):17531-17540 [PMID: 31405972]
  22. J Am Acad Dermatol. 2005 Oct;53(4):652-9 [PMID: 16198787]
  23. Br J Cancer. 2018 Jan;118(2):299-306 [PMID: 29161239]
  24. Adv Enzyme Regul. 1989;29:13-26 [PMID: 2561247]
  25. Stroke. 2004 Oct;35(10):2263-9 [PMID: 15345803]
  26. J Nutr Biochem. 2015 Oct;26(10):1084-94 [PMID: 26168702]
  27. Epilepsy Res. 2012 Nov;102(1-2):1-7 [PMID: 22824326]
  28. Xenobiotica. 2014 May;44(5):480-8 [PMID: 24494987]
  29. Ann Hum Genet. 2009 Sep;73(Pt 5):484-91 [PMID: 19650776]
  30. Am J Clin Nutr. 2014 Aug;100(2):593-9 [PMID: 24944062]
  31. Cancer Metastasis Rev. 2007 Mar;26(1):111-28 [PMID: 17334909]
  32. J Clin Psychiatry. 2016 May;77(5):654-60 [PMID: 27035404]
  33. Epilepsy Res. 2007 May;74(2-3):183-92 [PMID: 17448640]
  34. Br J Urol. 1977;49(7):673-8 [PMID: 597707]
  35. Eur J Nutr. 2019 Dec;58(8):3069-3077 [PMID: 30390106]
  36. Toxicol Rep. 2019 Sep 26;6:1018-1030 [PMID: 31673504]
  37. Lancet. 2007 Jun 2;369(9576):1876-1882 [PMID: 17544768]
  38. Birth Defects Res. 2021 Jan 1;113(1):77-89 [PMID: 33124747]
  39. J Nutr. 2015 Mar;145(3):520-31 [PMID: 25733468]
  40. Nutrients. 2011 Mar;3(3):370-84 [PMID: 22254102]
  41. J Transl Int Med. 2021 Dec 31;9(4):231-233 [PMID: 35136721]
  42. Arch Intern Med. 2001 Mar 12;161(5):695-700 [PMID: 11231701]
  43. Annu Rev Nutr. 2011 Aug 21;31:177-201 [PMID: 21568705]
  44. Rheumatology (Oxford). 2002 Jun;41(6):658-65 [PMID: 12048292]
  45. BMJ. 2002 Nov 23;325(7374):1202 [PMID: 12446535]
  46. Gene. 2000 Nov 27;258(1-2):117-25 [PMID: 11111049]
  47. Drug Metab Pharmacokinet. 2015 Jun;30(3):227-30 [PMID: 26003891]
  48. J Bone Miner Res. 2008 Jul;23(7):974-9 [PMID: 18442312]
  49. Epilepsy Res. 2007 Sep;76(2-3):113-23 [PMID: 17714918]
  50. Eur J Clin Nutr. 2020 Jul;74(7):1073-1083 [PMID: 32203239]
  51. QJM. 1995 May;88(5):357-64 [PMID: 7796091]
  52. J Pharmacol Sci. 2005 Aug;98(4):340-53 [PMID: 16079465]
  53. Nat Rev Cancer. 2013 Aug;13(8):572-83 [PMID: 23822983]
  54. Am J Clin Nutr. 2002 Jul;76(1):180-6 [PMID: 12081832]
  55. J Bone Miner Res. 2011 Dec;26(12):2991-3000 [PMID: 21898591]
  56. Mol Genet Metab. 2000 Aug;70(4):310-5 [PMID: 10993718]
  57. Scand J Rheumatol. 2001;30(5):305-7 [PMID: 11727846]
  58. J Am Diet Assoc. 2000 Jan;100(1):88-94 [PMID: 10646010]
  59. Semin Thromb Hemost. 2000;26(3):219-25 [PMID: 11011839]
  60. Lancet. 2006 Apr 22;367(9519):1352-61 [PMID: 16631914]
  61. J Transl Int Med. 2021 Dec 31;9(4):294-306 [PMID: 35136728]
  62. Am J Clin Nutr. 2013 Sep;98(3):668-76 [PMID: 23824729]
  63. Clin Chem Lab Med. 2003 Apr;41(4):547-53 [PMID: 12747601]
  64. Mol Pharmacol. 2008 Sep;74(3):854-62 [PMID: 18524888]
  65. Am J Clin Nutr. 2002 Feb;75(2):275-82 [PMID: 11815318]
  66. Expert Rev Mol Med. 2009 Jan 28;11:e4 [PMID: 19173758]
  67. Arterioscler Thromb Vasc Biol. 2018 Mar;38(3):679-685 [PMID: 29371246]
  68. J Transl Int Med. 2021 Dec 31;9(4):264-272 [PMID: 35136725]
  69. Epilepsia. 2007 Oct;48(10):1990-4 [PMID: 17561949]
  70. Am J Clin Nutr. 2010 Dec;92(6):1416-22 [PMID: 20844072]
  71. Clin Pharmacokinet. 2010 Aug;49(8):535-48 [PMID: 20608755]
  72. Am J Clin Nutr. 1997 Jun;65(6):1790-5 [PMID: 9174474]
  73. Mol Pharm. 2017 Nov 6;14(11):3848-3858 [PMID: 28885847]
  74. Am J Clin Nutr. 2005 May;81(5):1213S-1217S [PMID: 15883454]
  75. Nat Genet. 1995 May;10(1):111-3 [PMID: 7647779]
  76. Am J Clin Nutr. 2001 Apr;73(4):759-64 [PMID: 11273851]
  77. J Transl Int Med. 2021 Dec 31;9(4):239-248 [PMID: 35136723]
  78. J Nutr. 1999 Apr;129(4):779-82 [PMID: 10203550]
  79. Biofactors. 2011 Jul-Aug;37(4):269-71 [PMID: 21674649]
  80. J Nutr Biochem. 2004 Feb;15(2):64-79 [PMID: 14972346]
  81. Cancer Metastasis Rev. 2007 Mar;26(1):129-39 [PMID: 17340171]
  82. Cell Metab. 2017 Jan 10;25(1):27-42 [PMID: 27641100]
  83. Br J Nutr. 2006 Jan;95(1):145-51 [PMID: 16441927]
  84. J Clin Invest. 1996 Jul 1;98(1):177-84 [PMID: 8690790]
  85. Nutr Rev. 1997 May;55(5):145-9 [PMID: 9212690]
  86. Curr Opin Chem Biol. 2016 Feb;30:52-60 [PMID: 26629854]
  87. Am J Clin Nutr. 2017 May;105(5):1101-1109 [PMID: 28298392]
  88. Trends Neurosci. 2003 Mar;26(3):137-46 [PMID: 12591216]
  89. Am J Physiol Renal Physiol. 2006 Jul;291(1):F22-36 [PMID: 16760376]
  90. J Perinat Med. 2013 Sep 1;41(5):469-83 [PMID: 23482308]
  91. Epilepsia. 2012 Jan;53(1):120-8 [PMID: 22085257]
  92. Am J Clin Nutr. 2010 Feb;91(2):449-55 [PMID: 20007302]
  93. Am J Clin Nutr. 2005 Oct;82(4):806-12 [PMID: 16210710]
  94. Drug Metab Pharmacokinet. 2013;28(2):164-8 [PMID: 22971639]
  95. Blood. 2002 Nov 15;100(10):3832-4 [PMID: 12411325]
  96. Expert Opin Drug Saf. 2006 Jul;5(4):511-22 [PMID: 16774490]
  97. Mol Genet Metab. 2000 Sep-Oct;71(1-2):121-38 [PMID: 11001804]
  98. Am J Clin Nutr. 2006 Jul;84(1):156-61 [PMID: 16825690]

Word Cloud

Created with Highcharts 10.0.0folate5-methyltetrahydrofolatefolicacidmetabolismhomocysteinesupplementationprecisionseveraldiseasesusedsupplementhealthbioavailabilityone-carbonstudiesclearancecalcitriolvitamineffectscriticalonesizepersonalizedpoly-pathsFolatecrucialnutrientsupportsphysiologicalfunctionsLowlevelsriskfactorincludingcardiovascularneuraltubedefectssyntheticoxidativeformgrainfortificationsuccessstorypublicHowevermetabolicconversionbioactivetetrahydrofolaterequiresenzymescofactorsThereforefactorsinfluenceefficacycontrastdirectlyparticipatesusealternativeincreasedprimarilydependenttransmembranetransporterreducedcarriergenevariantfunctionalpolymorphismaffectsstatusindexesRecentdemonstratedexpressioncystathionineβ-synthaseanotherenzymerequiredincreasessignificantlyD3suggestingintakepromotessynergisticadvancementsbiomedicalcohortclinicaltrialsenhancedunderstandingrolesregulationanticipatefieldpoisedevolve3Psmeasuremeetindividualneedsmaximizebenefitsminimizesideevolution-nutritionD

Similar Articles

Cited By